Oraya Therapeutics

Wednesday, August 20, 2014 | New therapy tackles leading cause of blindness

Sheffield Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering appropriate patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD)…More >

Tuesday, August 5, 2014 |

Oraya® Therapeutics, Inc announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD). Researchers believe this work could lead to a better understanding of how gold nanoparticles activated by low-energy radiation therapy can act synergistically against cancers, including difficult-to-treat cancers of the eye, without damaging healthy tissue.>> Download Document

Tuesday, July 22, 2014 | ORAYA® THERAPEUTICS ANNOUNCES RAPID EXPANSION IN EUROPE AS MORE HOSPITALS OFFER ORAYA THERAPY FOR TREATING WET AMD

NEWARK, July 21, 2014 — Oraya Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany. Oraya Therapy is intended as a one-time, non-invasive treatment for wet Age-related Macular Degeneration, with the potential to maintain or enhance vision while significantly reducing the required number of anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
>> Download Document

Friday, November 15, 2013 | Initial Three-Year Data from INTREPID Study of Non-invasive Therapy for Wet AMD Presented at American Academy of Ophthalmology Annual Meeting

NEW ORLEANS, November 15, 2013 — Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology’s (AAO) annual meeting in New Orleans. The new data from 55 patients who have reached the three-year follow-up visit offer ongoing evidence of Oraya Therapy’s favorable safety profile.
Download Document
>> Download Document

Tuesday, November 12, 2013 | Oraya and OnCore Manufacturing Complete Production of Innovative Device for Wet AMD

NEWARK, CA and FREMONT, CA (Nov 12, 2013) — Oraya Therapeutics, Inc. and OnCore Manufacturing LLC announced today the production of the first commercial unit in the United States of the IRay® Radiotherapy System for the treatment of wet age-related macular degeneration (AMD), the leading cause of permanent vision loss in the industrialized world. IRay, the medical device at the core of Oraya Therapy, is CE marked and is currently available in the United Kingdom and Switzerland. The first commercial production comes as Oraya and OnCore have signed a long-term contract to facilitate Oraya’s continued expansion in Europe
>> Download Document

Wednesday, September 25, 2013 | Intrepid Study Demonstrates Two-Year Safety and Effectiveness of Non-Invasive Therapy For Wet AMD

NEWARK, CA (Sep 25, 2013) — Oraya Therapeutics, Inc. announced today the two-year results of its INTREPID study of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD). These results provide continued evidence of a favorable safety profile and the therapy’s ability to reduce the frequency of anti-vascular endothelial growth factor (VEGF) injections in the eye.
>> Download Document

Wednesday, August 14, 2013 | Groundbreaking Therapy For Wet AMD Now Available At Optegra Manchester Hospital

NEWARK, CA (Aug 14, 2013) — Oraya Therapeutics, Inc. announced today that the Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy. The non-invasive Oraya Therapy is intended as a one-time outpatient procedure to reduce the need for routine anti-vascular endothelial growth factor (anti-VEGF) injections into the eye.
>> Download Document

Thursday, April 18, 2013 | Oraya Therapeutics’ INTREPID Study Published in Ophthalmology, the official Journal of the American Academy of Ophthalmology

NEWARK, CA (Apr 18, 2013) — Oraya Therapeutics, Inc. today announced that results of its INTREPID study evaluating the safety and efficacy of Oraya Therapy™ Stereotactic Radiotherapy for the treatment of Wet Age-Related Macular Degeneration (AMD) have now been published, on-line in the leading peer-reviewed journal Ophthalmology. The study met primary endpoints, showing that a single dose of Oraya Therapy significantly reduces the need for anit-VEGF injections for patients with Wet AMD, with a favorable safety profile one year after administration.

>> Download Document

Thursday, April 4, 2013 | New Therapy for Wet AMD Introduced in Switzerland by Oraya® Therapeutics and EyeRAD

NEWARK, CA and BASEL, SWITZERLAND (Apr 4, 2013) — Oraya Therapeutics, Inc. and EyeRAD announced today that agreements have been reached to establish the Vista Klinik in Basel as one of the world’s first centers to offer the Oraya Therapy for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness in people over 65 in the Western world.

>> Download Document

Wednesday, February 27, 2013 | Oraya Therapy™ Continues to Show Efficacy for Wet Age-Related Macular Degeneration

NEWARK, CA. (FEB. 27, 2013) – Oraya Therapeutics, Inc. today announced that one of the patients who successfully was treated for wet age-related macular degeneration (AMD) with Oraya Therapy™ during the INTREPID clinical trial has released data showing he has experienced significant, sustained vision improvement more than two years after treatment in his right eye, without any subsequent anti-vascular endothelial growth factor (anti-VEGF) injections or other treatment.

>> Download Document

Tuesday, December 11, 2012 | New Therapy for Wet AMD Launched by Oraya Therapeutics and Optegra Eye Hospital Group

NEWARK, CA and LONDON, UK. (December 11, 2012) — Oraya Therapeutics, Inc. announced today that an agreement has been reached with UK specialist eye hospital group Optegra, to establish Optegra as the world’s first clinical centers to offer Oraya Therapy™ Stereotactic Radiotherapy for the treatment of wet Age-related Macular Degeneration (AMD).

>> Download Document

Thursday, November 22, 2012 | Trial Data Show Oraya Therapy Significantly Reduces Anti-VEGF Injections For Wet AMD

Oraya Therapeutics, Inc. today announces exciting late breaking results from a further analysis of the INTREPID trial using Oraya’s IRay® Radiotherapy System for wet AMD. The initial results were first presented during the 12th EURETINA Congress in Milan, Italy in September.

>> Download Document

Thursday, September 20, 2012 | Oraya Therapeutics Successful INTREPID Study Outcomes Presented at EURETINA 2012 Congress

Oraya Therapeutics, Inc. today announced that results of the INTREPID trial of radiation therapy for wet AMD were first presented during the 12th EURETINA Congress in Milan, Italy. The INTREPID study is the first sham-controlled double-masked trial to evaluate the effectiveness and safety of a one-time radiation therapy in conjunction with as-needed anti-VEGF injections for the treatment of wet AMD.

>> Download Document

Thursday, May 03, 2012 | Oraya Therapeutics Achieves Successful INTREPID Study Outcomes With a Non-Invasive Radiation Therapy for Wet AMD

Oraya Therapeutics, Inc. today announced that the INTREPID clinical trial of radiation therapy has met its primary endpoint of reduction in anti-VEGF injections for patients with wet age-related macular degeneration (wet AMD).

>> Download Document

Tuesday, May 17, 2011 | Oraya Completes Enrollment in Sham-Controlled Study of Radiation for Wet AMD

Oraya Therapeutics, Inc. today announced that it has completed enrollment of its INTREPID clinical trial in Europe. The study is the first sham-controlled, double-masked trial to evaluate the effectiveness and safety of radiation therapy in conjunction with standard of care anti-VEGF injections for the treatment of wet age-related macular degeneration (AMD).

>> Download Document

Monday, February 28, 2011 | King’s College Hospital First to Trial New Radiation Eye Treatment

>> Download Document

Wednesday, April 07, 2010 | Oraya Therapeutics Granted European CE Mark for the IRay Stereotactic Radiotherapy System

Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya’s IRay stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration.

>> Download Document

Tuesday, January 05, 2010 | Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD

Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD.

>> Download Document

Tuesday, October 20, 2009 | Oraya Therapeutics to present at Ophthalmology Innovations Summit

The Ophthalmology Innovation Summit (OIS), to be held at the Palace Hotel in San Francisco on October 22, 2009, will bring together leaders in the development of ophthalmic products, drugs, and devices. Oraya therapeutics will present a summary of its innovative technology, currently undergoing clinical evaluation for the treatment of wet macular degeneration. Additional information can be found at http://www.ophthalmologysummit.com.

>> Download Document

Tuesday, August 04, 2009 | Oraya Therapeutics Names JIM TAYLOR as President and Chief Executive Officer

Appointment of seasoned executive will support development of company’s age-related macular degeneration treatment

>> Download Document

Monday, July 20, 2009 | Oraya Therapeutics Raises $42 MILLION in Series C Financing

Company to begin international multi-center clinical trials for age-related macular degeneration treatment

>> Download Document

Back To Top

© 2014 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.